Literature DB >> 25331843

Reduced effect of percutaneous renal denervation on blood pressure in patients with isolated systolic hypertension.

Sebastian Ewen1, Christian Ukena2, Dominik Linz2, Ingrid Kindermann2, Bodo Cremers2, Ulrich Laufs2, Stefan Wagenpfeil2, Roland E Schmieder2, Michael Böhm2, Felix Mahfoud1.   

Abstract

Renal denervation can reduce blood pressure in certain patients with resistant hypertension. The effect in patients with isolated systolic hypertension (ISH, ≥140/<90 mm Hg) is unknown. This study investigated the effects of renal denervation in 126 patients divided into 63 patients with ISH and 63 patients with combined hypertension (CH, ≥140/≥90 mm Hg) defined as baseline office systolic blood pressure (SBP) ≥140 mm Hg despite treatment with ≥3 antihypertensive agents. Renal denervation significantly reduced office SBP and diastolic blood pressure (DBP) at 3, 6, and 12 months by 17/18/17 and 5/4/4 mm Hg in ISH and by 28/27/30 and 13/16/18 mm Hg in CH, respectively. The reduction in SBP and DBP in ISH was lower compared with patients with CH at all observed time points (P<0.05 for SBP/DBP intergroup comparison). The nonresponder rate (change in office SBP <10 mm Hg) after 6 months was 37% in ISH and 21% in CH (P<0.001). Mean 24-hour ambulatory SBP and DBP after 3, 6, and 12 months were significantly reduced by 10/13/15 and 6/6/9 mm Hg in CH, respectively. In patients with ISH the reduction in systolic ambulatory blood pressure was 4/8/7 mm Hg (P=0.032/P<0.001/P=0.009) and 3/4/2 mm Hg (P=0.08/P<0.001/P=0.130) in diastolic ambulatory blood pressure after 3, 6, and 12 months, respectively. The ambulatory blood pressure reduction was significantly lower after 3 and 12 months in SBP and after 12 months in ambulatory DBP, respectively. In conclusion, renal denervation reduces office and ambulatory blood pressure in patients with ISH. However, this reduction is less pronounced compared with patients with CH.
© 2014 American Heart Association, Inc.

Entities:  

Keywords:  isolated systolic hypertension; pulse pressure; renal denervation; resistant hypertension; sympathetic nervous system

Mesh:

Year:  2014        PMID: 25331843     DOI: 10.1161/HYPERTENSIONAHA.114.04336

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  35 in total

Review 1.  The rise, fall, and possible resurrection of renal denervation.

Authors:  Rajiv Gulati; Claire E Raphael; Manuela Negoita; Stuart J Pocock; Bernard J Gersh
Journal:  Nat Rev Cardiol       Date:  2016-02-04       Impact factor: 32.419

Review 2.  Hypertension: history and development of established and novel treatments.

Authors:  Milan Wolf; Sebastian Ewen; Felix Mahfoud; Michael Böhm
Journal:  Clin Res Cardiol       Date:  2018-06-27       Impact factor: 5.460

Review 3.  Modulation of Sympathetic Overactivity to Treat Resistant Hypertension.

Authors:  Raven Voora; Alan L Hinderliter
Journal:  Curr Hypertens Rep       Date:  2018-09-07       Impact factor: 5.369

4.  Impact of renal denervation on tissue Na+ content in treatment-resistant hypertension.

Authors:  Christian Ott; Christoph Kopp; Anke Dahlmann; Axel Schmid; Peter Linz; Alexander Cavallaro; Matthias Hammon; Tilmann Ditting; Roland Veelken; Michael Uder; Jens Titze; Roland E Schmieder
Journal:  Clin Res Cardiol       Date:  2017-08-28       Impact factor: 5.460

5.  Shaping the future of renal denervation-the relevance of sham-controlled randomized trials and recent meta-analyses.

Authors:  Márcio G Kiuchi; Jan K Ho; Leslie Marisol Lugo Gavidia; Markus P Schlaich
Journal:  Cardiovasc Diagn Ther       Date:  2019-12

Review 6.  Renal Denervation for Resistant Hypertension: Past, Present, and Future.

Authors:  Christian Ott; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2015-08       Impact factor: 5.369

Review 7.  Can we predict the blood pressure response to renal denervation?

Authors:  Gregory D Fink; Jeremiah T Phelps
Journal:  Auton Neurosci       Date:  2016-07-30       Impact factor: 3.145

Review 8.  Percutaneous Creation of a Central Iliac Arteriovenous Anastomosis for the Treatment of Arterial Hypertension.

Authors:  Stefan C Bertog; Nathan A Sobotka; Paul A Sobotka; Melvin D Lobo; Kolja Sievert; Laura Vaskelyte; Horst Sievert; Roland E Schmieder
Journal:  Curr Hypertens Rep       Date:  2018-03-19       Impact factor: 5.369

Review 9.  Renal sympathetic denervation in therapy resistant hypertension - pathophysiological aspects and predictors for treatment success.

Authors:  Karl Fengler; Karl Philipp Rommel; Thomas Okon; Gerhard Schuler; Philipp Lurz
Journal:  World J Cardiol       Date:  2016-08-26

Review 10.  Renal Denervation for Treatment of Hypertension: a Second Start and New Challenges.

Authors:  Alexandre Persu; Sverre Kjeldsen; Jan A Staessen; Michel Azizi
Journal:  Curr Hypertens Rep       Date:  2016-01       Impact factor: 5.369

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.